Johnson & Johnson MedTech has officially launched the ETHICON™ 4000 Stapler in the U.S., a next-generation surgical stapler designed to manage complex tissue challenges and reduce surgical complications such as leaks and bleeding. Featuring proprietary 3D Staple Technology and a redesigned end effector, the ETHICON 4000 delivers enhanced staple line integrity and consistent performance across open and laparoscopic procedures. It is also engineered for future use with the company’s upcoming OTTAVA™ Robotic Surgical System.
The ETHICON 4000 system will be showcased at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting from June 15–19, 2025, in Washington, D.C., where attendees can participate in live demonstrations and hands-on training.
“Surgical technology must evolve with the growing complexity of procedures,” said Hani Abouhalka, Company Group Chairman, Surgery, Johnson & Johnson MedTech. “The ETHICON 4000 reinforces our commitment to reducing surgical complications and improving consistency and safety across all surgical modalities.”
Stapling complications—particularly in bariatric, thoracic, and colorectal surgeries—can result in significant patient risk and carry an estimated $3 billion economic burden annually in the U.S. The ETHICON 4000 Stapler, used with ETHICON 3D Reloads, has been shown to reduce staple line interventions due to bleeding by 23% compared to traditional 2D staples. Its enhanced Gripping Surface Technology (GST) improves tissue stability, reducing slippage during stapling.
“The 3D technology ensures more even pressure distribution, giving me greater confidence in complex procedures,” said Dr. Kelvin Higa, Clinical Professor of Surgery at UCSF Fresno. “It’s an advancement that prioritizes both surgical outcomes and organizational value.”
Backed by real-world evidence, ETHICON stapling technology has consistently demonstrated improved outcomes since 2017. With FDA 510(k) clearance already granted for the ETHICON 4000 Stapler and 3D Reloads, the system is set to become commercially available in select U.S. hospitals soon.
Note: The OTTAVA™ Robotic Surgical System remains under development and is not yet authorized for commercial use.